Please regularly visit this section of our website for updates relating to the
Hever Group Survey on Covid-19 Pandemic
Pharmaceutical Companies have a long tradition of collaborating in pre-competitive partnerships to share data and knowledge. The Hever Group that comprises the most senior R&D Directors from the “Top 20” (by R&D spend) Pharmaceutical Companies was established 25 years ago by Prof Trevor Jones (formerly R&D DIrector at Wellcome) and meets annually together with the Directors of US FDA, NIH and the EU EMA .
One of its main aims is to reduce attrition in drug discovery and development and reduce time to market so to optimise patient access to new medicines and the ROI of R&D investment.
In recent years, following the SARS and Ebola outbreaks, the Group has discussed pandemic preparedness and its members have been closely associated with the recent C.E.P.I. initiative.
The Covid-19 pandemic demands that we collaborate to find drugs that could be repurposed and to find new drugs and vaccines against the virus.
As a matter of urgency, the Group commissioned a survey of what work is in progress . Given the rapidly changing scenarios, this will be updated as appropriate.
Click here to view report on Covid-19 from London Strategy.
Click here to view the Hever Group Survey on Covid-19 Pandemic.
Department of Health and Human Services, USA
Global Covid-19, Therapeutics Development, July 16th, 2020-Click here to view
The Academy of Medical Sciences-COVID-19 preclinical drug development database
This database aims to enhance the UK’s research response to COVID-19 by collating and sharing ongoing preclinical drug discovery and development research.
The International Pharmaceutical Federation (FIP)
Supporting Our members through the COVID-19 pandemic https://www.fip.org/coronavirus
Royal Pharmaceutical Society Coronavirus (COVID-19)
Pharmacist updates and information https://www.rpharms.com/coronavirus/